Immunotherapy

April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
January 26, 2022

Trial Spotlight: Jarushka Naidoo on the EAQ172 Trial for Steroid-Refractory Pneumonitis

This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
October 19, 2021

Remembering Martin “Mac” Cheever, MD

In September, the field of immunotherapy lost one of its pioneers
July 7, 2021

Now Enrolling: EA8192 for Upper Urinary Tract Cancer

This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021

Now Enrolling: EA2201 for Rectal Adenocarcinoma

This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
May 28, 2021

Trial Spotlight: Monika Joshi on the INSPIRE Study for Bladder Cancer

The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
March 31, 2021

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
February 25, 2021

Now Enrolling: EA3191 for Head and Neck Squamous Cell Carcinoma

This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
December 14, 2020

Reopened Trial: Jennifer Eads, MD on Study EA2174 for Esophageal and Gastroesophageal Cancer

EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma